JP2021532106A5 - - Google Patents
Info
- Publication number
- JP2021532106A5 JP2021532106A5 JP2021503095A JP2021503095A JP2021532106A5 JP 2021532106 A5 JP2021532106 A5 JP 2021532106A5 JP 2021503095 A JP2021503095 A JP 2021503095A JP 2021503095 A JP2021503095 A JP 2021503095A JP 2021532106 A5 JP2021532106 A5 JP 2021532106A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- agonist
- interferon type
- cell
- tumor
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222336A JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702172P | 2018-07-23 | 2018-07-23 | |
| US62/702,172 | 2018-07-23 | ||
| US201962788265P | 2019-01-04 | 2019-01-04 | |
| US62/788,265 | 2019-01-04 | ||
| PCT/IB2019/056259 WO2020021437A1 (en) | 2018-07-23 | 2019-07-22 | Compositions comprising bacterially derived minicells and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222336A Division JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532106A JP2021532106A (ja) | 2021-11-25 |
| JPWO2020021437A5 JPWO2020021437A5 (https=) | 2022-06-28 |
| JP2021532106A5 true JP2021532106A5 (https=) | 2022-06-28 |
Family
ID=69181384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503095A Pending JP2021532106A (ja) | 2018-07-23 | 2019-07-22 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
| JP2023222336A Pending JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222336A Pending JP2024038199A (ja) | 2018-07-23 | 2023-12-28 | 細菌由来ミニ細胞を含む組成物およびそれを使用する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11504402B2 (https=) |
| EP (1) | EP3826654A4 (https=) |
| JP (2) | JP2021532106A (https=) |
| CN (1) | CN112689511A (https=) |
| AU (2) | AU2019311380B2 (https=) |
| CA (1) | CA3107095A1 (https=) |
| SG (1) | SG11202100507PA (https=) |
| WO (1) | WO2020021437A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2858315C (en) | 2011-12-13 | 2020-05-12 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
| CN106999444B (zh) * | 2014-10-03 | 2023-12-12 | 安吉尼科分子传输公司 | 完整的细菌衍生的囊泡对小分子化合物的增强装载 |
| US11624061B2 (en) | 2017-04-28 | 2023-04-11 | Agrospheres, Inc. | Compositions and methods for enzyme immobilization |
| BR112020005803A2 (pt) | 2017-09-25 | 2020-12-01 | Agrospheres, Inc. | composições e métodos para produção e administração moduláveis de produtos biológicos |
| CN113507936A (zh) * | 2019-01-04 | 2021-10-15 | 安吉尼科分子传输公司 | 用于治疗赘生性疾病的包封的糖脂抗原 |
| WO2021191796A1 (en) * | 2020-03-24 | 2021-09-30 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, including coronavirus infections, and methods of using the same |
| US12357687B2 (en) | 2020-03-24 | 2025-07-15 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same |
| WO2022093729A1 (en) * | 2020-10-27 | 2022-05-05 | Rutgers, The State University Of New Jersey | Replication-defective vaccines and uses thereof |
| CN114569627A (zh) * | 2020-12-02 | 2022-06-03 | 杭州星鳌生物科技有限公司 | 新型sting激动剂复合物的制备、组成及其在抗肿瘤药物中的应用 |
| US12551550B2 (en) | 2021-07-22 | 2026-02-17 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same |
| WO2023002433A1 (en) * | 2021-07-22 | 2023-01-26 | Engeneic Molecular Delivery Pty Ltd | Compositions and vaccines for treating and/or preventing coronavirus variant infections and methods of using the same |
| CN121285390A (zh) * | 2023-04-17 | 2026-01-06 | 安吉尼科分子传输公司 | 用于递送α-半乳糖神经酰胺化合物的组合物和方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747002B2 (en) | 1999-05-11 | 2004-06-08 | Ortho-Mcneil Pharmaceutical, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| ATE541940T1 (de) | 2001-10-15 | 2012-02-15 | Engeneic Molecular Delivery Pty Ltd | Intakte minizellen als vektoren für dna-transfer und gentherapie in vitro und in vivo |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CN101954095B (zh) | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP1718338B1 (en) | 2004-02-02 | 2015-05-06 | EnGeneIC Molecular Delivery Pty Ltd. | Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| EP2386640B1 (en) * | 2004-08-26 | 2015-01-28 | EnGeneIC Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
| NZ573689A (en) | 2006-05-22 | 2011-03-31 | Univ New York | C-glycolipids with enhanced TH-1 profile |
| US9878043B2 (en) | 2006-06-23 | 2018-01-30 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
| DK2865755T3 (en) | 2007-03-30 | 2017-05-15 | Engeneic Molecular Delivery Pty Ltd | BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA |
| JP2010523724A (ja) | 2007-04-13 | 2010-07-15 | アカデミア シニカ | α−ガラクトシルセラミド類似体およびそれらの免疫療法剤としての使用 |
| DK2385980T3 (en) | 2009-01-08 | 2018-07-30 | Albert Einstein College Medicine Inc | BACTERIA VACCINES WITH CELL-WALL-ASSOCIATED CERAMIDE-LIKE GLYCOLIPIDS AND APPLICATIONS THEREOF |
| EP2496714B1 (en) * | 2009-11-04 | 2016-08-31 | DiamiR, LLC | Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment |
| ES2828092T3 (es) | 2012-10-02 | 2021-05-25 | Vaxiion Therapeutics Llc | Minicélulas inmunomoduladoras y métodos de uso |
| US9006200B2 (en) * | 2013-03-13 | 2015-04-14 | Asbestos Diseases Research Foundation | MicroRNA-based approach to treating malignant pleural mesothelioma |
| SG11201602429QA (en) * | 2013-10-04 | 2016-04-28 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
| KR20160106170A (ko) | 2014-01-22 | 2016-09-09 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체 및 항체-부하된 수지상 세포 매개된 요법을 위한 방법 및 조성물 |
| US10913940B2 (en) | 2016-04-11 | 2021-02-09 | University Of Virginia | Compositions and methods for pesticide degradation |
| AU2017339841B2 (en) * | 2016-10-06 | 2024-11-14 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
-
2019
- 2019-07-22 JP JP2021503095A patent/JP2021532106A/ja active Pending
- 2019-07-22 SG SG11202100507PA patent/SG11202100507PA/en unknown
- 2019-07-22 CA CA3107095A patent/CA3107095A1/en active Pending
- 2019-07-22 US US16/518,833 patent/US11504402B2/en active Active
- 2019-07-22 WO PCT/IB2019/056259 patent/WO2020021437A1/en not_active Ceased
- 2019-07-22 AU AU2019311380A patent/AU2019311380B2/en active Active
- 2019-07-22 CN CN201980060185.6A patent/CN112689511A/zh active Pending
- 2019-07-22 EP EP19839892.7A patent/EP3826654A4/en active Pending
-
2022
- 2022-11-18 US US17/990,402 patent/US12414968B2/en active Active
-
2023
- 2023-12-28 JP JP2023222336A patent/JP2024038199A/ja active Pending
-
2026
- 2026-03-17 AU AU2026202046A patent/AU2026202046A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532106A5 (https=) | ||
| JP6538031B2 (ja) | 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療 | |
| CN108779463B (zh) | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 | |
| CN109069528B (zh) | DBait分子在制备用于治疗三阴性乳腺癌的药物中的用途 | |
| US9701962B2 (en) | Hydrophobically modified antisense oligonucleotides comprising a ketal group | |
| JP2018100284A (ja) | 線維症および炎症状態を処置するための多標的調整 | |
| JPWO2020021437A5 (https=) | ||
| US11666664B2 (en) | Self assembling molecules for targeted drug delivery | |
| US20180201672A1 (en) | Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy | |
| CN111936150A (zh) | 抗癌微小rna及其脂质制剂 | |
| US20240043837A1 (en) | Modulation of signal transducer and activator of transcription 3 (stat3) expression | |
| JP2024504266A (ja) | リジン分解関連障害の治療 | |
| TW202327652A (zh) | 抗trop-2抗體及parp抑制劑之組合療法 | |
| CN105722979A (zh) | 肝癌相关的基因特异性siRNA、包含所述siRNA的双链寡RNA分子和包含它们的用于预防或治疗癌症的组合物 | |
| JP2019535816A (ja) | 癌治療のためのｓｉＲＮＡの使用 | |
| KR20250134181A (ko) | 핵산의 표적화된 전달을 위한 상승된 중성 지질 및 표적화 모이어티를 포함하는 지질 나노입자 | |
| EP3444345B1 (en) | microRNA-143 DERIVATIVE | |
| US20240124875A1 (en) | Rnai conjugates and uses thereof | |
| US20210102212A1 (en) | Cancer treatment by malat1 inhibition | |
| CN103108641B (zh) | Sdf-1结合性核酸及其在癌症治疗中的用途 | |
| CN111225922B (zh) | β连环蛋白核酸抑制剂分子 | |
| JP6973073B2 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| TW201932123A (zh) | 包含微小rna及其衍生物作為活性成分之藥物組成物 | |
| JPWO2020141495A5 (https=) | ||
| Abdelaal | Enhancing miRNA Therapeutics Using Ligand Conjugated and Chemically Modified Tumor Suppressive miRNAs |